[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342826-105":59,"doc-detail-342826-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","polymerase-i-as-a-target-for-treating-neurodegenerative-disorders","Polymerase I as a Target for Treating Neurodegenerative Disorders","","Polymerase I (Pol I) sits at the core of ribosomal RNA (rRNA) synthesis and represents an actionable therapeutic starting point. Because cellular mechanisms shared by cancer and neurodegeneration suggest common vulnerability, targeting Pol I or broader rRNA production may counter disorders driven by terminally differentiated neuron death. Protein accumulation, including abnormal α-synuclein and tau, motivates reducing protein output as a treatment direction. Pol I dysregulation may also relate to nucleolar stress, DNA damage, and childhood-onset neuronal death, and restricting Pol I activity may slow aging; however, safe modulation requires key answers about tolerance, timing, and compensatory responses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/polymerase-i-as-a-target-for-treating-neurodegenerative-disorders/342826/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/polymerase-i-as-a-target-for-treating-neurodegenerative-disorders/342826.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is Polymerase I (Pol I) considered a therapeutic target for neurodegenerative disorders?","Question",{"text":112,"@type":113},"Pol I is the rate-limiting driver of rRNA synthesis, linking it to the protein production pathway that supports neuronal function. The paper argues that targeting Pol I (or rRNA synthesis more broadly) is rational because of overlaps between cancer and neurodegeneration mechanisms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do abnormal proteins such as α-synuclein and tau relate to Pol I and treatment ideas?",{"text":117,"@type":113},"The document describes abnormal protein accumulation as an essential feature of disorders like Parkinson disease and fronto-temporal dementia. It then connects treatment rationale to reducing protein production, positioning Pol I as an upstream lever.",{"name":119,"@type":110,"acceptedAnswer":120},"What key questions must be answered before inhibiting Pol I for non-cancerous nervous system disorders?",{"text":121,"@type":113},"The article highlights uncertainty about how much Pol I inhibition neurons can tolerate and for how long, whether inhibition should be continuous or pulsed, and whether cells will compensate by increasing the number of active rDNAs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342826,1790147941,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","biomedicines  \nReview  \nPolymerase I as a Target for Treating Neurodegenerative Disorders  \nMark S. LeDoux 1,2  \nCitation: LeDoux, M.S. Polymerase I as a Target for Treating Neurodegenerative Disorders. Biomedicines 2024, 12, 1092 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biomedicines12051092  \nAcademic Editors: Ross Hannan and Denis Drygin  \nReceived: 31 March 2024  \nRevised: 6 May 2024  \nAccepted: 11 May 2024  \nPublished: 15 May 2024  \nCopyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Psychology and College of Health Sciences, University of Memphis, Memphis, TN 38152, USA; [msledoux@memphis.edu or mledoux@veracityneuroscience.com](msledoux@memphis.edu or mledoux@veracityneuroscience.com)  \n2 Veracity Neuroscience LLC, Memphis, TN 38157, USA  \nAbstract: Polymerase I (Pol I) is at the epicenter of ribosomal RNA (rRNA) synthesis. Pol I is a target for the treatment of cancer. Given the many cellular commonalities between cancer and neurodegeneration (i.e., different faces of the same coin), it seems rational to consider targeting Pol I or, more generally, rRNA synthesis for the treatment of disorders associated with the death of terminally differentiated neurons. Principally, ribosomes synthesize proteins, and, accordingly, Pol I can be considered the starting point for protein synthesis. Given that cellular accumulation of abnormal proteins such as 􀀋-synuclein and tau is an essential feature of neurodegenerative disorders such as Parkinson disease and fronto-temporal dementia, reduction of protein production is now considered a viable target for treatment of these and closely related neurodegenerative disorders. Abnormalities in polymerase I activity and rRNA production may also be associated with nuclear and nucleolar stress, DNA damage, and childhood-onset neuronal death, as is the case for the UBTFE210K neuroregression syndrome. Moreover, restraining the activity of Pol I may be a viable strategy to slow aging. Before starting down the road of Pol I inhibition for treating non-cancerous disorders of the nervous system, many questions must be answered. First, how much Pol I inhibition can neurons tolerate, and for how long? Should inhibition of Pol I be continuous or pulsed? Will cells compensate for Pol I inhibition by upregulating the number of active rDNAs? At present, we have no effective and safe disease modulatory treatments for Alzheimer disease, 􀀋-synucleinopathies, or tauopathies, and novel therapeutic targets and approaches must be explored.  \nKeywords: polymerase I; DNA; neurodegeneration; neuroregression; nucleolus; upstream binding transcription factor (UBTF)  \n1. Introduction  \nPolymerase I (Pol I) is the rate-limiting enzyme in the production of ribosomes [1,2] . Ribosomes are intricate ribonucleoprotein complexes that translate mRNA into protein [3] . The production of ribosomes utilizes a high percentage of intracellular energy and resources. In non-neuronal eukaryotic cells, well over 50% of active transcription is devoted to rRNA [4,5] . In the nucleolus, Pol I transcribes a 47S rRNA precursor (Figure 1) . Processing of this precursor into 28S, 18S, and 5.8S rRNA and pre-assembly of ribosomes also occur in the nucleolus [6,7] . Nucleolar assembly of ribosomes requires movement of ribosomal proteins, ribosomal biogenesis proteins, 5S rRNA, and snoRNAs into the nucleolus. Pre-assembled ribosomes are exported out of the nucleolus into the nucleus for further maturation and then into the cytoplasm for ﬁnal maturation. Abnormalities in ribosomes, the rate of ribosomal biogenesis, and the quality and quantity of protein production playa role in numerous","cbCaidPE9KTF0cnu","https://ap.wps.com/l/cbCaidPE9KTF0cnu","pdf",1006712,14,"English","# Abstract\n# Introduction","[{\"question\":\"Why is Polymerase I (Pol I) considered a therapeutic target for neurodegenerative disorders?\",\"answer\":\"Pol I is the rate-limiting driver of rRNA synthesis, linking it to the protein production pathway that supports neuronal function. The paper argues that targeting Pol I (or rRNA synthesis more broadly) is rational because of overlaps between cancer and neurodegeneration mechanisms.\"},{\"question\":\"How do abnormal proteins such as α-synuclein and tau relate to Pol I and treatment ideas?\",\"answer\":\"The document describes abnormal protein accumulation as an essential feature of disorders like Parkinson disease and fronto-temporal dementia. It then connects treatment rationale to reducing protein production, positioning Pol I as an upstream lever.\"},{\"question\":\"What key questions must be answered before inhibiting Pol I for non-cancerous nervous system disorders?\",\"answer\":\"The article highlights uncertainty about how much Pol I inhibition neurons can tolerate and for how long, whether inhibition should be continuous or pulsed, and whether cells will compensate by increasing the number of active rDNAs.\"}]","Polymerase I as a Target for Treating Neurodegenerative Disorders | PDF",1790048341,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac521081ad01f4514fcaf9f3fa54c483.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f55e05009fe21fbebb9c648c9ad14fd.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e1fc5a97ba0717cd3469512f8aca52b.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89834c7e2788c609fb9796901eec2800.webp",980,1385]